Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20799630 | 0.77 | RECQL (0.45) | DRD2DRD3 | |
| SCHEMBL25197084 | 0.77 | HTR2C (0.50) | CHRM4CHRM5 | |
| SCHEMBL10517083 | 0.77 | KCNH2 (0.61) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL10517086 | 0.77 | KCNH2 (0.61) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL5744278 | 0.77 | HRH3 (0.59) | DRD2 | |
| SCHEMBL5746137 | 0.76 | FUCA1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL9384270 | 0.75 | KCNH2 (0.60) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL9384273 | 0.75 | KCNH2 (0.60) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16766562 | 0.75 | CHRM2 (0.62) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4530898 | 0.75 | CHRM2 (0.58) | KCNH2OPRK1CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | KCNH2 3363/4885OPRK1 2965/4885CHRNB2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.